Clinical Trials Logo

Neonatal Abstinence Syndrome clinical trials

View clinical trials related to Neonatal Abstinence Syndrome.

Filter by:

NCT ID: NCT03718104 Recruiting - Clinical trials for Alcohol Use Disorder

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Start date: December 1, 2018
Phase:
Study type: Observational

This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone.

NCT ID: NCT03533985 Recruiting - NAS Clinical Trials

Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome

Start date: November 1, 2017
Phase: N/A
Study type: Interventional

This study examines the effects of 6 different music therapy interventions on outcomes for neonates diagnosed with Neonatal Abstinence Syndrome.

NCT ID: NCT03092011 Recruiting - Clinical trials for Neonatal Abstinence Syndrome

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

Start date: February 21, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether a medication, Clonidine can reduce the number of days a baby spends in the hospital and the number of days of medical treatment of withdrawal from Neonatal Abstinence Syndrome (NAS) as compared to Morphine Sulfate (used in routine care) .

NCT ID: NCT02249026 Recruiting - Withdrawal Clinical Trials

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Summary: There have been two published RCTs showing efficacy of buprenorphine treatment for NAS. However these trials excluded an estimated 22-47% of infants requiring pharmacologic treatment; those infants born to mothers with co-dependence on an opiate and a benzodiazepine. Although there are concerns, we anticipate that buprenorphine will be safe in this population. If it is safe, we can include these infants in the large double blind, double-dummy buprenorphine and clonidine vs. morphine and clonidine trial. If on the other hand, these infants have respiratory depression or other adverse events when buprenorphine is given, it will be important to report this study and caution the use of buprenorphine in these infants